Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines.

Marshall H, Clarke M, Sullivan T.

Vaccine. 2014 Jan 9;32(3):338-44. doi: 10.1016/j.vaccine.2013.11.042. Epub 2013 Nov 21.

PMID:
24269618
2.

Community, parental and adolescent awareness and knowledge of meningococcal disease.

Wang B, Clarke M, Afzali HH, Marshall H.

Vaccine. 2014 Apr 11;32(18):2042-9. doi: 10.1016/j.vaccine.2014.02.054. Epub 2014 Mar 1.

PMID:
24593997
3.

Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010.

Parrella A, Gold M, Marshall H, Braunack-Mayer A, Watson M, Baghurst P.

Hum Vaccin Immunother. 2012 May;8(5):662-7. doi: 10.4161/hv.19478. Epub 2012 May 1.

PMID:
22634441
4.

The missing link: family physician perspectives on barriers and enablers to prescribing a new Meningococcal B vaccine and other recommended, non-government funded vaccines.

Taylor KA, Stocks N, Marshall HS.

Vaccine. 2014 Jul 16;32(33):4214-9. doi: 10.1016/j.vaccine.2014.04.046. Epub 2014 Jun 9.

PMID:
24923639
5.

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL; 2001 Study Investigators.

Lancet Infect Dis. 2012 Aug;12(8):597-607. Epub 2012 May 7.

PMID:
22569484
6.

Parental perspectives of vaccine safety and experience of adverse events following immunisation.

Parrella A, Gold M, Marshall H, Braunack-Mayer A, Baghurst P.

Vaccine. 2013 Apr 12;31(16):2067-74. doi: 10.1016/j.vaccine.2013.02.011. Epub 2013 Feb 17.

PMID:
23422146
7.

Adolescent, parent and societal preferences and willingness to pay for meningococcal B vaccine: A Discrete Choice Experiment.

Marshall HS, Chen G, Clarke M, Ratcliffe J.

Vaccine. 2016 Jan 27;34(5):671-677. doi: 10.1016/j.vaccine.2015.11.075. Epub 2015 Dec 28.

PMID:
26740249
8.

Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.

Abdelnour A, Silas PE, Lamas MR, Aragón CF, Chiu NC, Chiu CH, Acuña TH, Castrejón Tde L, Izu A, Odrljin T, Smolenov I, Hohenboken M, Dull PM.

Vaccine. 2014 Feb 12;32(8):965-72. doi: 10.1016/j.vaccine.2013.12.034. Epub 2014 Jan 4.

PMID:
24397906
9.

Acceptability of meningococcal serogroup B vaccine among parents and health care workers in Italy: a survey.

Mameli C, Faccini M, Mazzali C, Picca M, Colella G, Duca PG, Zuccotti GV.

Hum Vaccin Immunother. 2014;10(10):3004-10. doi: 10.4161/21645515.2014.971602.

10.

A cross-sectional survey to assess community attitudes to introduction of Human papillomavirus vaccine.

Marshall H, Ryan P, Roberton D, Baghurst P.

Aust N Z J Public Health. 2007 Jun;31(3):235-42.

PMID:
17679241
12.

Vaccination against serogroup B Neisseria meningitidis: Perceptions and attitudes of parents.

Le Ngoc Tho S, Ader F, Ferry T, Floret D, Arnal M, Fargeas S, Chidiac C, Valour F.

Vaccine. 2015 Jul 9;33(30):3463-70. doi: 10.1016/j.vaccine.2015.05.073. Epub 2015 Jun 12.

PMID:
26055293
13.

Awareness is not enough: the need to increase meningococcal vaccine uptake.

Coyne-Beasley T, Reiter PL, Liberty AC, Ford CA, Miles DR, Brewer NT.

Clin Pediatr (Phila). 2013 May;52(5):441-50. doi: 10.1177/0009922813481847. Epub 2013 Mar 28.

PMID:
23539687
14.

Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults.

Bermal N, Huang LM, Dubey AP, Jain H, Bavdekar A, Lin TY, Bianco V, Baine Y, Miller JM.

Hum Vaccin. 2011 Feb;7(2):239-47. Epub 2011 Feb 1.

PMID:
21343698
15.

A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?

Martin NG, Snape MD.

Expert Rev Vaccines. 2013 Aug;12(8):837-58. doi: 10.1586/14760584.2013.814862. Review.

PMID:
23984957
16.
17.

Impact of a physician recommendation and parental immunization attitudes on receipt or intention to receive adolescent vaccines.

Gargano LM, Herbert NL, Painter JE, Sales JM, Morfaw C, Rask K, Murray D, DiClemente RJ, Hughes JM.

Hum Vaccin Immunother. 2013 Dec;9(12):2627-33. doi: 10.4161/hv.25823. Epub 2013 Jul 24.

18.

A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.

Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, Jansen KU, Perez JL.

Pediatr Infect Dis J. 2013 Apr;32(4):364-71. doi: 10.1097/INF.0b013e31827b0d24.

PMID:
23114369
19.

Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.

Toneatto D, Oster P, deBoer AC, Emerson A, Santos GF, Ypma E, DeTora L, Pizza M, Kimura A, Dull P.

Hum Vaccin. 2011 Jul;7(7):781-91. doi: 10.4161/hv.7.7.15997. Epub 2011 Jul 1.

PMID:
21734467
20.

Supplemental Content

Support Center